

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SANTARIS PHARMA A/S	03/22/2007
RECEIVING PARTY DATA	
Name:	ENZON PHARMACEUTICALS, INC.
Street Address:	685 Route 202/206
City:	Bridgewater
State/Country:	NEW JERSEY
Postal Code:	08807
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11271686
CORRESPONDENCE DATA	
Fax Number:	(646)728-2915
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	212.596.9000
Email:	andrew.shiue@ropesgray.com
Correspondent Name:	Jane T. Gunnison
Address Line 1:	Fish & Neave IP Group, Ropes & Gray LLP
Address Line 2:	1211 Avenue of the Americas
Address Line 4:	New York, NEW YORK 10036
ATTORNEY DOCKET NUMBER:	EPIP-4
NAME OF SUBMITTER:	Andrew Shiue
Total Attachments: 1 source=epip-0042#page1.tif	

CH \$40.00 11271686

SANTARIS PHARMA

ASSIGNMENT

WHEREAS the UNDERSIGNED, is an authorized officer of SANTARIS PHARMA A/S, a Danish Corporation having a principal place of business at Bøge Allé 3, DK-2970, Hørsholm, Denmark (SANTARIS) and whereas SANTARIS is the assignee of the entire worldwide right, title and interest in certain new and useful improvements (INVENTION) disclosed, shown, and described in an APPLICATION for Letters Patent of the United States of America entitled:

"POTENT LNA OLIGONUCLEOTIDES FOR INHIBITION OF HIF-1A EXPRESSION"

Said APPLICATION being identified as U.S. patent application serial no. 11/271,686, filed on November 9, 2005 and having an assignment recorded at Reel 018088 and Frame 0007 on July 6, 2006;

WHEREAS, ENZON PHARMACEUTICALS, INC., a Delaware Corporation having a principal place of business at 685 Route 202/206, Bridgewater, NJ 08807 (ENZON) is desirous of acquiring a one half undivided interest in and to the APPLICATION in the United States which may be granted embracing the INVENTION.

NOW, THEREFORE, for and in consideration of One Dollar (\$1.00) and for other good and valuable consideration, receipt of which is hereby acknowledged, SANTARIS assigns to ENZON, its successors and assigns a one half undivided interest for the United States, in and to the INVENTION, and in and to the APPLICATIONS for Letters Patent which have been or may be filed in the United States of America on said INVENTION, and in and to any and all priority rights generated by the filing of said APPLICATION in the United States of America, which may be granted covering the INVENTION, including any continuations, continuations-in-part, substitutions, divisions, reissues or renewals thereof, said Letters Patent in the United States of America.


SANTARIS shall, upon written request of ENZON and at ENZON's expense, give such assistance as ENZON may reasonably request to enable ENZON to (a) obtain Letters Patent, in the United States of America, on said INVENTION, (b) establish, maintain and secure title in said assignee, its successors and assigns, to said INVENTION, APPLICATION and Letters Patent, including making such title of lawful public record, and (c) perform such other acts as are necessary to give full force and effect to this assignment.

IN WITNESS WHEREOF this assignment has been executed by SANTARIS on the date opposite his name.

SANTARIS PHARMA A/S

DATE

April 27, 2007


Name: Keith McCullagh
Title: C.E.O.

Santaris Ref.: 1025US